Flow charts are also currently being developed ... The major risk is giving too little oxygen (hypoxia). Insufficient oxygen therapy can lead to cardiac arrhythmias, tissue damage, renal damage and, ...
U.S. commercial launch progressing on track with 33 authorized treatment centers as of March 19, 2025, following US FDA approval on November 8, 2024Obe-cel MHRA and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback